ERBB2 and neoplasm: According to current guidelines, patients with HER2-positive MRD but HER2-negative tumors are not eligible for anti-HER2-targeted treatment since only histologically proven HER2 status – either in the primary tumor or in a metastatic lesion – is taken into account.